SSR126768A (4-Chloro-3-[(3R)-(+)-5-chloro-1-(2,4-dimethoxybenzyl)-3-methyl-2- oxo-2,3-dihydro-1H-indol-3-yl]-N-ethyl-N-(3-pyridylmethyl)-benzamide, Hydrochloride): A New Selective and Orally Active Oxytocin Receptor Antagonist for the Prevention of Preterm Labor
- Claudine Serradeil-Le Gal,
- Gérard Valette,
- Loïc Foulon,
- Guy Germain,
- Charles Advenier,
- Emmanuel Naline,
- Marc Bardou,
- Jean-Pierre Martinolle,
- Brigitte Pouzet,
- Danielle Raufaste,
- Corinne Garcia,
- Eléonore Double-Cazanave,
- Maxime Pauly,
- Marc Pascal,
- Alain Barbier,
- Bernard Scatton,
- Jean-Pierre Maffrand and
- Gérard Le Fur
- Exploratory Research Department (C.S.L., G.V., L.F, B.P., D.R., C.G., E.D.-C., M.Pau., M.Pas.), General Pharmacology (J.P.Mar., A.B.) and Discovery Research Division (J.P. Maf., B.S., G.L.F.), Sanofi-Synthelabo Recherche, Toulouse, France; Unité Mixte Recherche Institut National de la Recherche Agronomique-Ecole Nationale Vétérinaire d'Alfort (G.G.), Physiologie du Développement et Reproduction, Bâtiment 231-Physiologie Animale, Centre de Recherches de Jouy, Institut National de la Recherche Agronomique, F78352 Jouy en Josas Cedex, France; Unité de Formation et de Recherche Biomedicale des St Pères (C.A., E.N.), Paris, France; and Faculty of Medecine (M.B.), Dijon, France
- Address correspondence to:
Dr. C. Serradeil-Le Gal, Sanofi-Synthélabo Recherche, Exploratory Research Department, 195 route d'Espagne, 31036 Toulouse Cedex, France. E-mail: claudine.serradeil{at}sanofi-synthelabo.com
Abstract
4-Chloro-3-[(3R)-(+)-5-chloro-1-(2,4-dimethoxybenzyl)-3-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-N-ethyl-N-(3-pyridylmethyl)benzamide, hydrochloride (SSR126768A), a new potent and selective, orally active oxytocin (OT) receptor antagonist was characterized in several biochemical and pharmacological models. In binding studies, SSR126768A showed nanomolar affinity for rat and human recombinant and native OT receptors (Ki = 0.44 nM) and exhibited much lower affinity for V1a, V1b, and V2 receptors. In addition, it did not interact with a large number of other receptors, enzymes, and ion channels (1 μM). In autoradiographic experiments performed on at-term human pregnant uterus sections, SSR126768A dose dependently displaced [I125]d(CH2)5[Tyr(Me)2, Thr4, Orn8125I-Tyr-NH29]VT in situ labeling to OT receptors highly expressed in these tissues. In functional studies, SSR126768A behaved as a full antagonist and potently antagonized OT-induced intracellular Ca2+ increase (Ki = 0.50 nM) and prostaglandin release (Ki = 0.45 nM) in human uterine smooth muscle cells. In rat isolated myometrium, OT-induced uterine contractions were competitively antagonized by SSR126768A (pA2 = 8.47). Similarly, in human pregnant myometrial strips, SSR126768A inhibited the contractile uterine response to OT. In conscious telemetrated rats, oral administration of SSR126768A (1-10 mg/kg) produced a competitive inhibition of the dose response to OT on uterine contractions up to 24 h at 3 mg/kg p.o.; no tachyphylaxis was observed after 4-day repeated treatment. Finally, SSR126768A (30 mg/kg p.o.) significantly delayed parturition in pregnant rats in labor similar to ritodrine (10 mg/kg p.o.). Thus, SSR126768A is a potent, highly selective, orally active OT receptor antagonist with a long duration of action. This molecule could find therapeutic application as a tocolytic agent for acute and chronic oral management of preterm labor.
Footnotes
-
DOI: 10.1124/jpet.103.061200.
-
ABBREVIATIONS: OT, oxytocin; AVP, arginine vasopressin; OTR, oxytocin receptor; SSR126768A, 4-chloro-3-[(3R)-(+)-5-chloro-1-(2,4-dimethoxybenzyl)-3-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-N-ethyl-N-(3-pyridylmethyl)-benzamide, hydrochloride; SSR149515, ((2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide, isomer(-)); SR49059, ((2S)-1-[(2R,3S)-(5-chloro-3-(2-chlorophenyl)-1-(3,4-dimethoxybenzenesulfonyl)-3-hydroxy-2,3-dihydro-1H-indole-2-carbonyl]-pyrrolidine-2-carboxamide); SR121463A, (1-[4-(N-tert-butylcarbamoyl)-2-methoxybenzene sulfonyl]-5-ethoxy-3-spiro-[4-(2-morpholinoethoxy)cyclohexane]indol-2-one, fumarate, equatorial isomer; PG, prostaglandin; AM, acetoxymethyl ester; UtSMC, uterine smooth muscle cell; [125I]OVTA, d(CH2)5[Tyr(Me)2, Thr4, Orn8 125I-Tyr-NH29]VT; CHO, Chinese hamster ovary; [Ca2+]i, intracellular Ca2+; ANOVA, analysis of variance; IUP, intrauterine pressure.
-
- Received October 10, 2003.
- Accepted December 18, 2003.
- The American Society for Pharmacology and Experimental Therapeutics



